BioBridge Global adds two industry leaders to Regenerative Medicine Advisory Board

May 6, 2019

regen_board_bbgBioBridge Global  has added two new members to its Regenerative Medicine Advisory Board, a group composed of industry leaders with a wide range of scientific, product development and business experience brought together to support the organization’s continued growth in regenerative medicine

BioBridge Global provides a range of products and services in regenerative medicine, including human cells and tissue, testing, and biomanufacturing and clinical services, through its three operating entities: GenCure, QualTex Laboratories and the South Texas Blood & Tissue Center.

The new members of the BioBridge Global Regenerative Medicine Advisory Board are:

  • Chris Mason, PhD, Co-founder and Chief Science Officer at AvroBio, a publicly held, clinical-stage, gene therapy company based in Cambridge, Massachusetts. Dr. Mason is a professor of cell and gene therapy at University College London. He also is Senior Editor of the journals Cell and Gene Therapy Insight and Regenerative Medicine.
  • Michael J. Yaszemski, MD, PhD, Professor of Orthopedic Surgery and Biomedical Engineering at the Mayo Clinic and director of its Biomaterials and Tissue Engineering Laboratory. Dr. Yaszemski served as Chair of the FDA Center for Devices and Radiologic Health Advisory Committee, and is currently a member of the FDA Science Board. He is a retired U.S. Air Force brigadier general.

Extended biographies are here.

The addition of new advisory board members comes at a time when BioBridge Global is launching the second phase of its GenCure biomanufacturing capacity expansion. The 21,000-square-foot facility will produce the large numbers of consistent, high-quality, clinical-grade adult stem cells needed to help bring potential new therapies into human clinical trials. The center is expected to be completed by the end of 2019.

“With the addition of Chris and Mike, we now have five outstanding industry leaders that will help lead BioBridge Global become a recognized leader in regenerative medicine,” said Martin Landon, Chief Executive Officer of BioBridge Global. “Their invaluable experience and expertise will guide our research and development in breakthrough cellular therapies that ultimately will save and enhance lives.”

The BioBridge Global Regenerative Medicine Advisory Board was formed in 2018 and includes Phil Vanek, PhD, General Manager of GE Healthcare’s Cell and Gene Therapy business strategy; Gregory Bonfiglio, JD, Founder and Managing Partner of Proteus LLC, an investment and advisory firm focused solely on regenerative medicine, and Chairman of the Board of the Centre for Commercialization of Regenerative Medicine in Toronto, Canada; and Kenneth Bertram, MD, PhD, FACP, former commander of the Walter Reed Army Institute of Research and Principal Assistant for Acquisition for the U.S. Army Medical Research and Materiel Command.